Elekta AB Unsponsored ADR Class B ( (EKTAY) ) has released its Q3 earnings. Here is a breakdown of the information Elekta AB Unsponsored ADR Class B presented to its investors.
Elekta AB Unsponsored ADR Class B is a leading medical technology company specializing in innovative solutions for treating cancer and brain disorders, primarily operating in the radiotherapy sector. In its latest earnings report for the third quarter of the 2024/25 fiscal year, Elekta demonstrated solid performance with a 3% increase in reported net sales, driven by strong growth in the European and APAC regions, although sales were negatively impacted by lower volumes in the U.S. and China. The company’s book-to-bill ratio improved to 1.15, indicating strong order growth across all regions and business lines, bolstered by successful launches of new products like Elekta Evo and Elekta ONE. Despite challenges in key markets, Elekta’s adjusted EBIT rose by 4% to SEK 548 million, and net income increased by 10% to SEK 336 million, with earnings per share up 12%. The company achieved record cash flow in the quarter, attributed to cost-control measures and product mix improvements, although it anticipates broadly stable net sales and a lower EBIT margin for the full fiscal year. Looking ahead, Elekta remains cautiously optimistic, focusing on leveraging its robust product portfolio to drive future growth and improve profitability, targeting an EBIT margin of 14% or higher beyond the current fiscal year.